Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has
Author: TNN Bureau
Clinical and genetic features of cardiomyopathy reported from multiple large familial cases in India
Hypertrophic cardiomyopathy (HCM) affects the health of the heart muscle. Genetic cause of 40-50% of HCM are not known. The mutations responsible for HCM often
Symkevi/Kalydeco cleared for use in young CF patients
The European Commission as approved use of Vertex’ Symkevi (tezacaftor/ivacaftor) with Kalydeco (ivacaftor) for eligible children with cystic fibrosis (CF) aged 6-11 years. The combination
EU to review Merck’s targeted lung cancer drug
European regulators will review Merck’s tepotinib for a specific type of lung cancer, having validated the drug’s marketing application. Tepotinib is designed to treat advanced
NICE turns down Novartis’ Adakveo
Novartis’ Adakveo (crizanlizumab) has hit a setback having failed to gain acceptance by the National Institute for Health and Care Excellence (NICE). The cost watchdog
NHS to trial innovative cancer blood test
The NHS is trialling an innovative new blood test that may be able to detect more than 50 types of cancer. The Galleri blood test,
NICE backs use of new treatment for multiple myeloma
Patients with a difficult to treat form of multiple myeloma will now gain access to a new treatment on the NHS in England and Wales,
Moderna signs deal with EU for 160 million COVID-19 vaccine doses
The European Commission (EC) has signed a supply deal with Moderna which will see it secure an initial 80 million doses of the US biotech’s
Janssen’s Tremfya approved for active psoriatic arthritis
The European Commission has approved Janssen’s Tremfya (guselkumab) as a first-in-class treatment for active psoriatic arthritis (PsA). The decision allows doctors to prescribe the drug
Mixed reaction to chancellor’s spending review
Chancellor Rishi Sunak has unveiled the government’s spending plans for the coming year, outlining funding plans for the NHS, clinical research and research and development.